That's fantastic.
This is another question for both of you or one of you.
Price is considered to be a poor determinant of where new medicines are first launched. Many countries with lower drug prices than Canada, including the Netherlands, Sweden, the U.K. and Norway, have obtained earlier access to new medicines. I think this is an important question for all of us, but for Canadians watching, can you explain how the new guidelines will encourage further pharmaceutical innovation in Canada?